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A B S T R A C T
The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in
the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229). In this 52-
week sub-analysis of the open-label extension of REGAIN (NCT02301624), eculizumab’s efficacy and safety were
assessed in 11 Japanese and 88 Caucasian patients with anti-acetylcholine receptor antibody-positive refractory
generalized myasthenia gravis. For patients who had received placebo during REGAIN, treatment with open-
label eculizumab resulted in generally similar outcomes in the Japanese and Caucasian populations. Rapid
improvements were maintained for 52 weeks, assessed by change in score from open-label extension baseline to
week 52 (mean [standard error]) using the following scales (in Japanese and Caucasian patients, respectively):
Myasthenia Gravis Activities of Daily Living (−2.4 [1.34] and−3.3 [0.65]); Quantitative Myasthenia Gravis
(−2.9 [1.98] and− 4.3 [0.79]); Myasthenia Gravis Composite (−4.5 [2.63] and−4.9 [1.19]); and Myasthenia
Gravis Quality of Life 15-item questionnaire (−8.6 [5.68] and−6.5 [1.93]). Overall, the safety of eculizumab
was consistent with its known safety profile. In this interim sub-analysis, the efficacy and safety of eculizumab in
Japanese and Caucasian patients were generally similar, and consistent with the overall REGAIN population.
1. Introduction
Anti-acetylcholine receptor antibody-positive (AChR+) generalized
myasthenia gravis (gMG) is a rare autoimmune disorder characterized
by severe muscle weakness. In patients with this disorder, antibodies to
the acetylcholine receptor (AChR) can activate the complement cas-
cade, which causes structural damage to the neuromuscular junction
(NMJ) [1–3]. These complement-mediated changes lower the efficiency
of neurotransmission at the NMJ resulting in muscle weakness and fa-
tigability that are characteristic of myasthenia gravis (MG) [2].
In approximately 10–15% of all patients with MG, the signs and
symptoms of MG are inadequately controlled by immunosuppressive
therapies (ISTs) [4–6]. In these patients with refractory MG, health-
related quality of life and activities of daily living are often significantly
impacted, and the risk of experiencing MG crises, exacerbations, hos-
pitalizations, and emergency room visits remains higher than in
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patients who do respond to ISTs [7,8].
Eculizumab is a humanized monoclonal antibody specifically tar-
geted to human terminal complement protein C5 [9]. It is approved in
Japan for the treatment of gMG in patients whose symptoms are diffi-
cult to control with high-dose intravenous immunoglobulin or plas-
mapheresis [10]. Its safety and rapid and sustained efficacy in patients
with AChR+ refractory gMG have been reported previously [11,12].
Differences between the clinical characteristics of MG in Japanese
patients and in populations that are mainly Caucasian have been de-
scribed, particularly with regard to a peak in the incidence of infantile-
onset MG, comprising predominantly cases of ocular MG, in Japanese
and other Asian populations [13,14]. Furthermore, different human
leukocyte antigen alleles have been associated with age of MG onset
[15] and have been reported in Japanese and other Asian patients
compared with those seen in Caucasian patients with MG [16,17]. It is
not known whether such differences in genetic background may influ-
ence the response of Japanese patients with MG to eculizumab.
To investigate the efficacy and safety of eculizumab in Japanese
patients, we report a sub-analysis of interim data from Japanese and
Caucasian participants in the open-label extension of the REGAIN
study.
2. Materials and methods
2.1. Study design and study population
Eligible participants entered the open-label study within 2 weeks of
completing their REGAIN week 26 visit. Patients from 72 centers in 17
countries were included in the open-label study, which started on 12
November 2014 and was completed in January 2019. This sub-analysis
examined the effects of eculizumab in Japanese patients, defined as
those of Japanese descent and living in Japan, and compared their
outcomes with those of Caucasian participants. To simplify this eva-
luation, because the majority of patients in REGAIN were Caucasian
[11], all non-Japanese, non-Caucasian patients were excluded. Conse-
quently, this sub-analysis reports the efficacy and safety of eculizumab
in 11 Japanese and 88 Caucasian patients at the 31 December 2017
data cut-off.
For REGAIN, patients were randomized to receive placebo or ecu-
lizumab, with stratification according to Myasthenia Gravis Foundation
of America classification at screening; patients were not randomized
within countries or centers because the numbers of patients for each
location were anticipated to be low [11]. Full REGAIN inclusion and
exclusion criteria have been reported [11]. Key inclusion criteria were:
confirmed gMG with a positive serologic test result for anti-AChR an-
tibodies; a total score on the Myasthenia Gravis Activities of Daily
Living scale (MG-ADL) of 6 or higher; and received and failed treatment
with two or more ISTs, or with one or more ISTs and chronic plasma
exchange therapy or intravenous immunoglobulin at least four times
over the previous 12months. A history of thymoma or other thymic
neoplasms was a key criterion for exclusion. Patients were required to
have been vaccinated against Neisseria meningitidis. During REGAIN,
patients previously receiving ISTs were required to maintain their pre-
study dose and schedule; in the open-label study, adjustment of con-
comitant ISTs was permitted at the discretion of the investigator.
However, adjustment of ISTs was not required by the study protocol or
requested by the sponsor.
Written informed consent was obtained from all patients before
entering the open-label study. The study was conducted in accordance
with the Declaration of Helsinki, and the study protocol was approved
by the appropriate ethics committee for each study site.
2.2. Dosing and administration of eculizumab
To preserve the blinded nature of REGAIN, open-label study parti-
cipants entered a 4-week, double-blind induction phase before the
open-label maintenance phase [12]. Patients from the placebo arm of
REGAIN received eculizumab during the open-label study (placebo/
eculizumab group). During the induction phase, these patients received
eculizumab 900mg each week for 4 weeks. Patients from the REGAIN
eculizumab arm continued to receive eculizumab (eculizumab/eculi-
zumab group), and during the induction phase, they received eculi-
zumab 1200mg on day 1 and at week 2, and matched placebo at week
1 and week 3. During the open-label maintenance phase, all patients
received open-label eculizumab 1200mg every 2 weeks starting at
week 4.
2.3. Assessments
This sub-analysis presents open-label study data for the period up to
52weeks. The same validated MG-specific assessment tools as in
REGAIN were used to evaluate activities of daily living (MG-ADL) [18],
muscle strength (Quantitative Myasthenia Gravis scale [QMG]) [19],
functional ability (Myasthenia Gravis Composite scale [MGC]) [20],
and quality of life (Myasthenia Gravis Quality of Life 15-item ques-
tionnaire [MG-QoL15]) [21]. MG-ADL, QMG, and MGC were assessed
at day 1 and also weekly to week 4; MG-QoL15 was assessed at day 1
and then at week 4. All four assessments were performed at weeks 8,
12, 16, 20, 26, 40, and 52 in year 1, and then every 6months or at
termination if this was before the study ended.
In addition, Myasthenia Gravis Foundation of America (MGFA)
post-intervention status was assessed relative to REGAIN baseline at
open-label study week 52. Patients who were categorized as improved
(having achieved a substantial decrease in clinical manifestations or in
MG medications) were also evaluated for minimal manifestations
(having no symptoms of functional limitations from MG but having
some weakness on examination of some muscles) and pharmacologic
remission (having no symptoms or signs of MG [no weakness of any
muscle on examination, other than isolated weakness of eyelid closure]
for at least 1 year while receiving some form of therapy for MG other
than cholinesterase inhibitors) [22].
Efficacy endpoints included change from open-label study baseline
and change from REGAIN baseline in mean MG-ADL, QMG, MGC, and
MG-QoL15 total scores, and MGFA post-intervention status (improved,
minimal manifestations, pharmacologic remission) [22].
Safety assessments included adverse events and serious adverse
events. The incidences of MG exacerbations and hospitalizations were
also recorded. For the open-label study, an exacerbation is defined as:
an MG crisis; significant symptomatic worsening (to a score of 3 or a 2-
point worsening on any one of the individual MG-ADL items, excluding
ocular items); or requirement for rescue therapy.
2.4. Statistical analysis
Efficacy analyses were conducted using data from Japanese and
Caucasian patients in the full analysis set, which comprised all patients
who received at least one dose of eculizumab in the open-label study
and had at least one post-infusion efficacy assessment. Safety analyses
were performed using the safety set (all patients who received at least
one dose of eculizumab in the open-label study).
Two baselines were used for efficacy analyses. The open-label study
baseline was defined as the last available assessment before the first
infusion of eculizumab in the open-label study. This was typically the
day 1 assessment in the open-label study; if the day 1 data were
missing, the most recent assessment from REGAIN was used as the
open-label baseline. The REGAIN baseline was the day 1 assessment for
REGAIN.
Efficacy analyses were based on separate repeated-measures models
for each of the treatment groups. Assessing the change from the open-
label baseline allows for evaluation of the effect of eculizumab treat-
ment in the placebo/eculizumab arm, and the effect of continuing
treatment in the eculizumab/eculizumab arm. The change from
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REGAIN baseline allows for an assessment of all changes over time
following continued exposure to eculizumab. Missing data for MG-ADL,
QMG, MGC, and MG-QoL15 scores were not imputed. This sub-analysis
provides descriptive statistics for Japanese and Caucasian patients in
the placebo/eculizumab group; because the number of Japanese pa-
tients in the eculizumab/eculizumab group was low, data for this group
were not separated by race. Data are reported as means and corre-
sponding standard error of the means.
3. Results
3.1. Demographic and disease characteristics
As of 31 December 2017, a total of 117 patients had enrolled into
the open-label study and had received at least one dose of eculizumab.
Eighteen patients who were neither Japanese nor Caucasian were ex-
cluded from this sub-analysis (eight were Asian but not Japanese, two
black, six of other race, one of multiple races, and one of unknown
race). A total of 99 patients were included in this sub-analysis: 11
Japanese patients (eight received placebo and three were treated with
eculizumab in REGAIN) and 88 Caucasian patients (45.5% [40/88]
from Europe, 43.2% [38/88] from North America and 11.4% [10/88]
from South America; 41 received placebo and 47 received eculizumab
during REGAIN). The male/female ratio and age at first study drug dose
were similar for Japanese and Caucasian patients, although Japanese
patients tended to weigh less than Caucasian patients (Table 1). Disease
burden, evaluated by MG-ADL, QMG, MGC, and MG-QoL15 scores and
MGFA classification, in each group at open-label baseline is presented
in Table 1.
In this interim sub-analysis of the extension study, all eight
Japanese patients and 36/41 Caucasian patients (88%) in the placebo/
eculizumab group had received eculizumab for at least 52 weeks. In the
eculizumab/eculizumab group, 43/50 patients (86%) had received
eculizumab for at least 52 weeks in the open-label study; therefore, the
majority of patients in this group had received eculizumab for at least
78 weeks (including 26weeks’ treatment in REGAIN).
3.2. Efficacy analyses
3.2.1. Changes from open-label extension study and REGAIN baselines for
the Japanese and Caucasian placebo/eculizumab groups
During the 26-week REGAIN study, some degree of placebo re-
sponse was observed, and the eight Japanese patients showed a
stronger placebo response than the Caucasian patients, especially for
changes in mean MG-ADL, MGC, and MG-QoL15 total scores (Fig. 1).
During the open-label study blinded-induction phase, the Japanese
patients in the placebo/eculizumab group generally had rapid im-
provements in response to eculizumab in mean MG-ADL, QMG, MGC,
and MG-QoL15 total scores (Fig. 1, Fig. 2). The placebo/eculizumab-
treated Caucasian patients also had rapid responses to eculizumab
during the induction phase. While the change from REGAIN baseline
was greater in the Japanese patients than in Caucasian patients (Fig. 1),
the change from open-label baseline was similar between the two
groups (Fig. 2). Improvements in all measures were sustained through
52weeks. The patterns of improvements with eculizumab in the open-
label study observed for these patients in the placebo/eculizumab
group were also similar to those observed for eculizumab-treated pa-
tients in REGAIN.
After 52 weeks of open-label eculizumab therapy, 62.5% (5/8) of
Japanese patients in the placebo/eculizumab group achieved an MGFA
post-intervention status of minimal manifestations or pharmacologic
remission, compared with 69.4% (25/36) of Caucasian patients.
3.2.2. Changes from open-label extension study and REGAIN baselines for
the eculizumab/eculizumab-treated patients
For the eculizumab/eculizumab group (Japanese and Caucasian
patients together), the improvements seen during REGAIN were sus-
tained through 52weeks during the open-label study (Fig. 1, Fig. 2). In
Table 1
Baseline demographics and disease characteristics of Japanese and Caucasian patients in the open-label extension study.
Treatment group Placebo/eculizumab Eculizumab/eculizumab
Patient group Japanese (n=8) Caucasian (n=41) All (N=49) Japanese (n=3) Caucasian (n=47) All (N=50)
Age at start of open-label study (years), mean (SD) 55.0 (12.9) 49.4 (18.2) 50.3 (17.4) 39.7 (5.7) 49.9 (15.1) 49.3 (14.9)
Sex, n (%)
Male 2 (25.0) 16 (39.0) 18 (36.7) 1 (33.3) 17 (36.2) 18 (36.0)
Female 6 (75.0) 25 (61.0) 31 (63.3) 2 (66.7) 30 (63.8) 32 (64.0)
Weight (kg)
n 8 40 48 3 47 50
Mean (SD) 62.2 (19.3) 96.5 (29.4) 90.8 (30.6) 60.7 (8.0) 91.1 (28.6) 89.2 (28.7)
Ethnicity, n (%)
Hispanic or Latino 0 (0.0) 9 (22.0) 9 (18.4) 0 (0.0) 6 (12.8) 6 (12.0)
Not Hispanic or Latino 8 (100.0) 30 (73.2) 38 (77.6) 3 (100.0) 38 (80.9) 41 (82.0)
Not reported/unknown 0 (0.0) 2 (4.9) 2 (4.1) 0 (0.0) 3 (6.4) 3 (6.0)
Region, n (%)
Europe 0 (0.0) 15 (36.6) 15 (30.6) 0 (0.0) 25 (53.2) 25 (50.0)
North America 0 (0.0) 20 (48.8) 20 (40.8) 0 (0.0) 18 (38.3) 18 (36.0)
South America 0 (0.0) 6 (14.6) 6 (12.2) 0 (0.0) 4 (8.5) 4 (8.0)
Japan 8 (100.0) 0 (0.0) 8 (16.3) 3 (100.0) 0 (0.0) 3 (6.0)
MG duration, mean (SD), yearsa 7.39 (7.166) 9.76 (8.365) 9.37 (8.160) 11.67 (8.038) 10.42 (8.037) 10.49 (7.961)
MG-ADL score, mean (SD) 6.4 (3.16) 7.7 (3.66) 7.4 (3.59) 11.0 (1.73) 5.6 (4.28) 5.9 (4.35)
QMG score, mean (SD) 11.9 (6.27) 14.4 (5.80) 14.0 (5.88) 19.3 (7.02) 12.1 (5.32) 12.5 (5.63)
MGC score, mean (SD) 10.8 (5.85) 13.2 (7.36) 12.8 (7.14) 19.3 (8.08) 10.3 (7.66) 10.8 (7.91)
MG-QoL15 score, mean (SD) 25.0 (15.05) 23.3 (14.14) 23.6 (14.15) 25.3 (8.08) 19.3 (16.26) 19.7 (15.90)
MGFA classification by randomization stratification, n (%)
Class IIa or IIIa 4 (50.0) 21 (51.2) 25 (51.0) 2 (66.7) 21 (44.7) 23 (46.0)
Class IVa 1 (12.5) 0 (0.0) 1 (2.0) 0 (0.0) 3 (6.4) 3 (6.0)
Class IIb or IIIb 3 (37.5) 18 (43.9) 21 (42.9) 1 (33.3) 20 (42.6) 21 (42.0)
Class IVb 0 (0.0) 2 (4.9) 2 (4.1) 0 (0.0) 3 (6.4) 3 (6.0)
MG, myasthenia gravis; MG-ADL, Myasthenia Gravis Activities of Daily Living scale; MGC, Myasthenia Gravis Composite scale; MGFA, Myasthenia Gravis Foundation
of America; MG-QoL15, Myasthenia Gravis Quality of Life 15-item questionnaire; QMG, Quantitative Myasthenia Gravis scale; SD, standard deviation.
a Time from MG diagnosis to first dose date in the REGAIN study.
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this group, 44.2% (19/43) of patients achieved an MGFA post-inter-
vention status of minimal manifestations or pharmacologic remission
after 52 weeks of open-label eculizumab therapy. Three Japanese pa-
tients were randomized to receive eculizumab in REGAIN and con-
tinued in the eculizumab/eculizumab arm; however, only one Japanese
patient in this group continued in the open-label study after week 26.
3.3. Safety analyses
In total, 99 patients were included in the safety analysis set
(Table 2). The most frequently reported adverse events were headache
(36.4% of Japanese patients, 37.5% of Caucasian patients) and naso-
pharyngitis (100.0% of Japanese patients, 23.9% of Caucasian pa-
tients). At the time of this sub-analysis, serious adverse events were
experienced by 45.5% of Japanese patients (5/11; four in the placebo/
eculizumab group, and one in the eculizumab/eculizumab group) and
46.6% of Caucasian patients (41/88; 19 in the placebo/eculizumab
group and 22 in the eculizumab/eculizumab group; Table 3, and Table
A in Supplementary material). No Japanese patients in either group
experienced any MG crises, whereas 2.3% of Caucasian patients (2/88;
one in each group) each experienced one event.
At the time of this interim sub-analysis, 22 patients (3 Japanese and
19 Caucasian) had discontinued from the open-label study (placebo/
eculizumab group: 1 Japanese patient and 10 Caucasian patients; ecu-
lizumab/eculizumab group: 2 Japanese patients and 9 Caucasian pa-
tients; Table 2). One Japanese patient in each treatment group with-
drew from the study and one in the eculizumab/eculizumab group was
withdrawn by their physician. No Japanese patients discontinued
owing to adverse events, and no deaths were reported through week 52.
Eight Caucasian patients elected to withdraw from the study, and four
were withdrawn by their physician (placebo/eculizumab group: 6 and
2, respectively; eculizumab/eculizumab group: 2 and 2, respectively).
In addition, three Caucasian patients discontinued owing to serious
adverse events: one discontinuation was due to MG clinical deteriora-
tion (placebo/eculizumab group), one was due to MG crisis, and one
was due to rectal abscess. One additional patient discontinued for a
reason recorded as ‘other’ (eculizumab/eculizumab group).
Three Caucasian patients died; all had comorbidities that were
likely to have contributed to these outcomes. The first death (in the
eculizumab/eculizumab group) occurred in a patient who was receiving
concomitant azathioprine, and was attributed to hemophagocytic
lymphohistiocytosis associated with cytomegalovirus infection of the
liver resulting in hepatic failure and multi-organ failure. This death was
considered by the investigator to be probably related to study treat-
ment. The second death from pulmonary embolism (placebo/eculi-
zumab group) occurred in a hospitalized patient who had a history of
pulmonary disease and was recovering from cardiogenic shock sec-
ondary to sepsis, which was complicated by a deep vein thrombosis.
The third death (eculizumab/eculizumab group) was attributed to end-
stage liver disease in a patient with a history of liver disease including
fatty liver and cryptogenic liver cirrhosis. The latter two deaths were
considered by the investigators to be unlikely to be related to study
treatment.
Exacerbations were experienced by 27.3% of Japanese patients and
18.2% of Caucasian patients. Hospitalization related to worsening of
MG was required by 36.4% of Japanese patients and 10.2% of
Caucasian patients. No meningococcal infections occurred as of the
interim analysis cut-off date; one case occurred after this date in a
Caucasian female patient who received antibiotics and recovered.
4. Discussion
Published data suggest that the prevalence of MG in Japan increased
between 1987 and 2006 [13], possibly owing to improvements in di-
agnostic accuracy and patient follow-up, as well as increased longevity.
Another survey (1999–2000) showed that up to 70% of Japanese pa-
tients with MG who had received standard treatment had persistent
ocular or generalized weakness that may result in moderate or severe
disability [23]. The Japanese guidelines for MG treatment were up-
dated in 2014 to emphasize the importance of patients’ quality of life
[24–26]. These changes were informed by a large retrospective analysis
of Japanese patients with MG that evaluated factors impacting on
quality of life, and recommended using early, fast-acting treatment
strategies [27]. Such treatment strategies have demonstrated improved
outcomes for Japanese patients compared with other approaches using
conventional therapies; however, these strategies are not effective for
all patients [27], suggesting that new, innovative treatment approaches
would be of benefit in these patients.
The safety and rapid and sustained efficacy of the terminal com-
plement inhibitor eculizumab have been demonstrated in the phase 3
REGAIN study and its open-label extension in an international popu-
lation of patients with AChR+ refractory gMG [11,12]. It is possible
that previously described differences in clinical and genetic character-
istics between Japanese and Caucasian patients with MG [13,16,17]
may impact the immunopathogenesis of MG and thus influence pa-
tients’ responses to therapy. We have therefore investigated the efficacy
and safety of eculizumab in Japanese patients with refractory gMG in
the REGAIN open-label extension study.
This sub-analysis of interim data from the REGAIN open-label ex-
tension study has shown that the rapid and sustained improvements
observed during eculizumab treatment in REGAIN [11], and during the
open-label study in Caucasian patients who had received placebo
during REGAIN, were also seen in the small number of Japanese pa-
tients who commenced eculizumab therapy at the start of the open-
label study. Notably, over half of both Japanese and Caucasian patients
who had refractory gMG at the start of REGAIN achieved minimal
manifestations of MG after 52 weeks of open-label eculizumab therapy.
Table 2
Safety information for all Japanese and Caucasian patients in the open-label
study.
Patients, n (%)
Japanese
(n=11)
Caucasian
(n=88)
All
(N=99)
Deaths 0 (0.0) 3a (3.4) 3 (3.0)
Discontinuations 3 (27.3) 19 (21.6) 22 (22.2)
Hospitalizations due to worsening
of myasthenia gravis
4 (36.4) 9 (10.2) 13 (13.2)
Patients with protocol-defined
exacerbation
3 (27.3) 16 (18.2) 19 (19.2)
Patients requiring rescue therapy 3 (27.3) 18 (20.5) 21 (21.2)
Most-common adverse events
occurring in ≥10% of total
patientsb
Headache 4 (36.4) 33 (37.5) 37 (37.4)
Nasopharyngitis 11 (100.0) 21 (23.9) 32 (32.3)
Diarrhea 1 (9.1) 23 (26.1) 24 (24.2)
Arthralgia 1 (9.1) 18 (20.5) 19 (19.2)
Myasthenia gravis 3 (27.3) 15 (17.0) 18 (18.2)
Pain in extremity 2 (18.2) 15 (17.0) 17 (17.2)
Nausea 1 (9.1) 16 (18.2) 17 (17.2)
Influenza 2 (18.2) 13 (14.8) 15 (15.2)
Bronchitis 1 (9.1) 12 (13.6) 13 (13.1)
Gastroenteritis 1 (9.1) 12 (13.6) 13 (13.1)
Urinary tract infection 1 (9.1) 12 (13.6) 13 (13.1)
Pyrexia 1 (9.1) 11 (12.5) 12 (12.1)
Contusion 2 (18.2) 9 (10.2) 11 (11.1)
Gastroenteritis viral 1 (9.1) 9 (10.2) 10 (10.1)
Seasonal allergy 1 (9.1) 9 (10.2) 10 (10.1)
Back pain 2 (18.2) 8 (9.1) 10 (10.1)
Muscle spasm 2 (18.2) 8 (9.1) 10 (10.1)
a Causes of death were hepatic failure, chronic hepatic failure, and pul-
monary embolism (one patient each).
b Adverse events with onset on or after the date of the first eculizumab dose
in the open-label study.
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The placebo effect observed in the REGAIN study has been discussed
previously and could have been influenced by factors such as more
frequent follow-up in the study than in usual clinical practice, or the
expected variability of MG symptoms over time [11]. Interestingly, the
eight Japanese patients who received placebo for 26weeks in REGAIN
exhibited a stronger placebo response than that experienced by Cau-
casian patients in the placebo group. The reasons for this difference are
not known, but there was more variability in response in the Japanese
patients than in the Caucasian patients, probably owing to the small
number of Japanese patients overall. On commencement of eculizumab
therapy after receiving placebo during REGAIN, improvements during
the blinded-induction phase and up to 52weeks in the maintenance
phase of the open-label study were of similar magnitude in Japanese
and Caucasian patients.
The safety profiles of eculizumab in Japanese and Caucasian pa-
tients during the open-label study were consistent with those reported
for eculizumab-treated patients in REGAIN [11] and in studies in aty-
pical hemolytic uremic syndrome and paroxysmal nocturnal hemoglo-
binuria [28–30]. No new safety concerns were identified in Japanese
participants. No meningococcal infections occurred during this interim
analysis period; one case occurred after this in a Caucasian patient who
recovered [12]. The three patients who died during the open-label ex-
tension were Caucasian [12].
A limitation of this sub-analysis is the low number of Japanese
patients, who constituted a relatively small proportion (9.4%) of the
overall open-label study population. Furthermore, because randomi-
zation in REGAIN occurred across all centers, the numbers of patients
assigned to eculizumab or placebo could be dissimilar for participating
countries. This resulted in the imbalance whereby three Japanese pa-
tients received eculizumab in REGAIN while eight received placebo.
Because of this distribution, Japanese and Caucasian patients were
compared only in the placebo/eculizumab group, in which most pa-
tients received at least 52 weeks’ eculizumab exposure. Some differ-
ences that were observed between Japanese and Caucasian patients in
this sub-analysis, for example in the rates of MG exacerbations and MG-
related hospitalizations, may be due to the small number of Japanese
patients included. While the sample size and patient distribution in
REGAIN and the open-label extension may limit generalizations about
similarities between Japanese and Caucasian patients in terms of re-
sponse to eculizumab, this sub-analysis from the open-label extension
provides data on the efficacy and safety of eculizumab for at least
52 weeks in Japanese patients with AChR+ refractory gMG that is not
adequately treated using other methods, such as chronic intravenous
immunoglobulin and/or plasma exchange therapy.
This interim sub-analysis of the REGAIN open-label extension
showed that open-label eculizumab was well tolerated and demon-
strated similar clinical benefits in both Japanese and Caucasian pa-
tients, which were sustained for at least 52 weeks. Eculizumab is
therefore a useful therapeutic option for Japanese patients with diffi-
cult-to-control AChR+ gMG. The completion of the open-label study is
expected to provide additional long-term efficacy and safety data.
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